Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Silver Supply Deficit with Demand Increasing bodes well for Silver Miners
https://www.zerohedge.com/markets/why-powerful-silver-bull-market-may-be-ahead
https://www.zerohedge.com/markets/why-powerful-silver-bull-market-may-be-ahead
50 this year.....100 next ....?
https://www.zerohedge.com/markets/why-powerful-silver-bull-market-may-be-ahead
Silver has a long way before hitting a top
Heres some mention of PDA
https://mexicobusiness.news/mining/news/alamos-golds-success-mexico-first-look-mmf-2024-pdac
It appears very promising and high grade.
https://www.kitco.com/news/article/2024-04-17/silver-see-second-highest-deficit-20-years-record-industrial-demand-rises-9
Huge silver demand..... much greater than supply. Bullish for silver / precious metals mining companies like AG, PAAS, AGI, et al
NAK is the elephant in the room when it comes to gold / silver / copper sites that are undeveloped.
https://stockcharts.com/h-sc/ui?s=NAK&p=D&b=5&g=0&id=p12546101316
Gold chart is skyrocketing and even today keeps on climbing up. NAK has tremendous potential.
https://stockcharts.com/h-sc/ui?s=%24GOLD&p=D&b=5&g=0&id=p90797131442
Gold / Silver Miners have started to breakout. chart 94
https://stockcharts.com/public/1107832/tenpp/9
Nice update...bright future
https://www.goldforumeurope.com/company-session/3188/
There was mention of "PDA"...can anyone expand on that and explain a bit ?
Precious Metals going to the moon.. on a fast track up. It will only help NAK in the short term
and the long run.
Is there a Silver Squeeze in the future..... ????
Action Seeks to overturn EPA’s illegal veto 03.15.24 NEWS
One action, in Federal District Court in Alaska, seeks to vacate the Environmental Protection Agency’s (“EPA”) veto of a development at Pebble. This is the main focus of our legal actions. We are confident that the court will vacate the EPA veto and allow permitting of the Pebble project to resume because, as we have previously stated, the veto violated the law and was arbitrary and capricious. The complaint in this action alleges, among many other points, the veto was issued in violation of various federal statutes regarding Alaska’s statehood rights and a land exchange approved by Congress; it was based on an overly broad legal interpretation of EPA’s jurisdiction which has since been over-ruled by the Supreme Court; its geographic scope exceeds that allowed by the statute; it was based on information previously developed by EPA in an illegal preemptive veto process that was designed to reach a predetermined result; and the factual basis stated to support the veto is directly contradicted by the July 2020 Environmental Impact Statement published by the United States Army Corps of Engineers (“USACE”), which is an important part of the administrative record. The EPA has not demonstrated that either the development of the Pebble deposit will have unacceptable adverse effects under Section 404(c), or that there are any impacts to Bristol Bay fisheries that would justify the extreme measures in the final determination (veto).
Wow...What hoppened today........
Looks like a descending triple bottom breakdown. !!!!! ..
https://stockcharts.com/freecharts/gallery.html?envx
Now Honda and GM working together in a 50 - 50 LLC
https://www.asahi.com/ajw/articles/15154331
Certainly creates a question about the direction of EV for me.
The article however, does say "affordable" but it does not say "how affordable"
it will be and that is a real question for me.
Scott ....thanks for your very often repeated opinion, but in only the last
20 years its been to 2, 3, 5, 10, and even over 20 dollars per share......
https://www.google.com/finance/quote/NAK:NYSEAMERICAN?window=MAX
so I don't mind loading a few bargain basement shares to keep in the closet for a few years and then
unload at some point in time. My guess is that it wll be at a much higher price, which will happen sooner or later and I think NAK is loaded with potential. Big potential.
phenomenal potential....absolutely phenomenal potential Only needs development...
https://northerndynastyminerals.com/pebble-project/reserves-resources-1/
Updates from the home page...
https://northerndynastyminerals.com/
Wondering if this type of new Toyota engine will become big competition for EV's,
or if it is another good but, failed idea in the end, and ENVX will emerge as the
the winner in all this technology.
rollup....great work rollup...greatly appreciated, all excellent news, and a reason to remain very hopeful. 😀
selected quotes from your link.........w the Indian Journal of Critical Care Medicine
"Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS:"
"Background: Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in COVID. We share our experience with this molecule by doing a retrospective study to evaluate the effect of this drug on clinical outcomes in viral-related ARDS patients."
"Conclusion: Aviptadil has shown to improve the clinical outcomes in patients with severe viral-related ARDS without any adverse effects"
Any old figures for the global dollar value of ARDS medications out there.. ???
Pegs, ...very sympathetic about your interstitial lung issues. Hopes and prayers for big improvements in the new year. The progress with aviptadil is disappointing for me at this time. ... I have hoped there will be some much better progress with big pharma in india or japan or especially a swiss company. Still hoping for a better 2024....
Interesting company in solid state battery tech is ENVX fyi
MONY....that sounds great,
appreciate the info ....but do you have a link for that. TIA
would like the go all in on ENVX, but I have been burned too many times, so
any links would be greatly appreciated.
https://oilprice.com/Energy/Energy-General/Toyotas-Solid-State-Battery-Boasts-745-Miles-On-A-10-Minute-Charge.html
Will or is ENVX be in this ballpark.?? Does not look like Toyota will be using ENVX, so gotta ask who.
Re Music... What type of compensation you think we could get?
I had a significant position, for me, in the lower 5 figures, with Barrick Gold a number of years back, easily over 10 years ago...
Barrick got sued similiarly.. I had lost a bunch of dinero...........It took a lot of work to put together all the trades and data required for the suit....
Then it took YEARS for a judgement.....Always thought it would be a nice payoff from the suit...
I finally wound up with a check for less than $20 bucks in a final settlement.... It wasnt even worth the time to put all the paperwork bull sheet together.. The lawyers are the only ones that make any money. Plain and Simple. Maybe some huge Fund Accounts get a few bucks.
Sadly no one likes to take a loss, but if anyone thinks this suit will amount to a big jackpot they are delusional IMHO. Lawyers file suits all the time against wall street stocks
https://www.zerohedge.com/commodities/copper-critical-americas-new-energy-economy
Anyone know a company that has incredible large vast amounts of copper waiting to be mined for developing a new energy grid and powering EV production. ?
I bet plenty of countries would like to have an asset like that.
Maybe we can import copper from China eh ?
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
https://finance.yahoo.com/news/relief-therapeutics-announces-more-400-052000953.html
GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced that over 400,000 of its ADRs are now outstanding. Since one of the key requirements for a NASDAQ listing of ADRs is the requirement that a company have more than 400,000 ADRs outstanding at the time of its initial listing, this important milestone has now been achieved. If Relief is successful in listing its ADRs on the NASDAQ Stock Market, Relief's ADR listing will complement the existing listing of its ordinary shares on the SIX Swiss Exchange.
Relief Therapeutics Holdings AG, Friday, May 26, 2023, Press release picture
Relief Therapeutics Holdings AG, Friday, May 26, 2023, Press release picture
"We are pleased that our shareholders have contributed ordinary shares in return for ADRs in an effort to aid in our objective of listing our ADRs on a U.S. national securities exchange," said Jack Weinstein, chief executive officer of Relief. "Once the remaining requirements for listing are met, which primarily includes achieving a market price of $4.00 per ADR, we intend to progress quickly towards a NASDAQ listing of our ADRs." Mr. Weinstein continued, "Achieving a listing of our ADRs on a U.S. national exchange will broaden the pool of institutional investors able to invest both with open market purchases of our ADRs and in potential future U.S. offerings. We believe that Relief can obtain a NASDAQ listing status by the end of this year, and we are currently exploring several avenues to meet the remaining NASDAQ initial listing requirements."
https://quotes.freerealtime.com/quotes/RLFTF/Time%26Sales
safe and effective.......mgmt needs to to broadcast the message... looks like a
new round of covid being mfg.
Up, up on nice volume today.
Is good news on the way ?
Up over 8 percent today on no news and low volume.
Any one with any info ??
thanks for the update....
attached is a link.......a change is coming for NAK at some point in time.
This is a unusual rare UNANIMOUS start.
https://www.msn.com/en-us/news/politics/supreme-court-delivers-blow-to-key-biden-environmental-policy-in-unanimous-ruling/ar-AA1bGPIM
Thank you PW. Thats very helpful.
Now if Relief will only help with some block buster good news.
And at the end of an extensive and exhaustive appeals process, with gold over
$7500 per oz and momentum to push it over $10,000 per oz, the US dollar
in grave peril, along with the US in desperate need of strategic materials, their
emerges an different attitude about approvals for NAK.
..........Down the road...... at some point no doubt.....ying and yang. .
It might then be too late to buy in at a decent price. ....
Additional news........
https://finance.yahoo.com/news/relief-therapeutics-announces-swissmedic-approval-053000247.html
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
The state-of-the-art quality control and research and development laboratory in Balerna, Switzerland is run by APR Applied Pharma Research SA, a Relief Therapeutics subsidiary
GENEVA, SWITZERLAND / ACCESSWIRE / May 15, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFFD)(OTCQB:RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced its new state-of-the-art laboratory has been audited and approved by the Swiss Agency for Therapeutic Products (Swissmedic) and meets Good Manufacturing Practice (GMP) standards. Swissmedic is the national authorization and supervisory authority for drugs and medical products and devices.
The next-generation laboratory in Balerna, Switzerland is run by Relief Therapeutics' subsidiary APR Applied Pharma Research SA (APR) and offers a comprehensive suite of analytical and development services for internal projects and provides external clients with data and full documentation to meet current Good Manufacturing Practice (cGMP), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and international regulatory authority requirements.
"GMP compliance is a critical achievement for our laboratory, enabling us to create, safeguard and supply high-quality products to patients and healthcare providers as well as enable the future submissions of product files to regulatory authorities," said Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR. "Our new GMP lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with the current technical and analytical R&D capabilities, with more than 800 m 2 equipped for analytical and formulation development of solid and non-solid dosage forms."
The modern analytical laboratory is part of APR's overall upgrade of the research and development facilities and equipment in Balerna, which now includes four new state-of-the-art high performance liquid chromatography (HPLC) systems equipped for method scouting, new analytical scales, viscometers, physical testing instruments as well as a new packaging area equipped with filling and blistering machines to pack research and development prototypes for stability studies.
"We are excited that our new GMP-compliant lab in Balerna, where innovation is driven by our experienced and highly talented employees, is now Swissmedic-approved and operational," said Jack Weinstein, chief executive officer of Relief Therapeutics. "APR is a trusted and experienced formulator and developer, which has been validated by the breadth and quality of its contract service partners and products that have been developed over more than 30 years."
....Oddly, IMHO, I would think that RFL would want this on their web site....if only in reference to APR ....... any explaination ?
Yes, its getting pretty stale. Or some of the existing long term holders are bailing. Really at a point where some great news would go a long way.
Need the mgmt / office holders to buy in here. That would be a huge statement for all the shareholders as would be some very positive news.
Thanks PW.
IMHO....Relief needs to make some deals with some companies in counties like Switzerland, India and or Japan.
Any Approvals for ARDS would be huge......Whats the hold up ?
I wonder why some of the approvals by India can not be combined with Relief in order to market to other parts of the globe without the US involvement.
Further, I always thought that a RS would allow the big fund companies to buy in but so far its not looking that way. .
.
Right now is seems even the ticker symbols are a bit fuzzy to me.....
Seems to me this news would have made RLF a big mover
a year and a half back. I sort of think RLF needs some approvals for ARDS, C 19, etc, or team up with another company or country, like Japan, Korea, India, or a BP Swiss company
like Roche or Novartis.
.
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Holding SA / Key word(s): Research Update
17-Apr-2023 / 07:00 CET/CEST
GENEVA (April 17, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced positive 12-month stability data for the liquid and lyophilized preparations of RLF-100®, intended for intravenous (IV) and inhaled administration. RLF-100® is the company’s proprietary, investigational formulation of aviptadil acetate.
The data from the stability study showed that both inhaled and IV RLF-100® demonstrated high purity levels at 12 months at all temperatures tested, including refrigerated and room temperature environments. The results are consistent with prior data observed at three- and six-month intervals. The stability testing study will continue to determine the maximum shelf life of RLF-100®.
Based on the latest results, Relief Therapeutics intends to amend its previously filed provisional patent application for RLF-100® with the new findings. If granted, this patent could provide exclusivity for RLF-100® at least until 2042, without considering Hatch-Waxman extensions or other patent term adjustments. The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process.
“The testing conducted to date has consistently shown that our novel, optimized composition of aviptadil acetate provides better stability results in both the liquid and lyophilized preparations. RLF-100® was shown to be shelf stable and active after one year at temperatures suitable for shipping and long-term storage. This is an important milestone toward commercialization to ensure that RLF-100® is safe and effective, no matter where in the world it is supplied.” said Jack Weinstein, chief executive officer at Relief Therapeutics. “We believe this new, stable formulation has significant clinical and commercial value and our goal is to establish RLF-100® as the standard of care for the prevention and treatment of respiratory failure and its complications in both the acute and chronic applications.”
Stability testing of pharmaceutical products is mandatory for regulatory approvals. If a product fails to meet the standards prescribed by regulatory authorities, the product will not be granted approval for commercialization. Planning, execution and completion of studies in given timelines plays a major role in securing approval and ensuring a product reaches patients who need it.
RLF-100® is under development for the potential treatment of acute and chronic lung diseases, including pulmonary sarcoidosis, infectious acute respiratory distress syndrome (ARDS), checkpoint inhibitor-induced pneumonitis (CIP) and chronic berylliosis. The U.S. Food and Drug Administration (FDA) granted RLF-100® Orphan Drug designation (ODD) to inhaled RLF-100® for the potential treatment of pulmonary sarcoidosis in August 2021.
https://www.relieftherapeutics.com/newsblog-detail/?newsID=2490653
Bullish Long Term........
As prices climb higher and higher......Nak will become impossible to ignore.
https://www.zerohedge.com/markets/ppi-plunge-prompts-panic-bid-big-tech-bullion-bitcoin
https://twitter.com/search?q=Relief%20Therapeutics&src=typed_query&f=live
GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities. The medical affairs team will report to Paolo Galfetti, chief operating officer at Relief Therapeutics, until a replacement is hired. Clinical development and regulatory responsibilities will continue to be supported by consultants already contracted with the Company.
"We have established strong medical affairs and research and development teams that will continue to serve us well as we focus our resources to advance our metabolic, connective tissue and pulmonary rare disease programs forward," said Jack Weinstein, chief executive officer at Relief Therapeutics. "We have moved our pipeline through several important milestones over the past year, and we appreciate Nermeen's contributions to those efforts. We wish Nermeen success in her future endeavors."
RT Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
https://www.relieftherapeutics.com/newsblog-detail/?newsID=2482011
GENEVA, APRIL 3, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announces the appointment of world-renowned gene therapy pioneer Guangping Gao, Ph.D. as the chair of the Company’s newly formed scientific advisory board (SAB). Dr. Gao is the co-director of the Li Weibo Institute for Rare Diseases Research, director of the Horae Gene Therapy Center and Viral Vector Core, professor of microbiology and physiological systems, and Penelope Booth Rockwell Chair in biomedical research at the University of Massachusetts Chan Medical School in Worcester, Mass.
Internationally recognized in the field of gene therapy, Dr. Gao played a key role in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field, significantly impacting many currently untreatable human diseases.
“Dr. Gao is a distinguished and accomplished academic and genetic medicine leader who has made fundamental discoveries in gene therapy that have pushed the field forward. He brings an unparalleled combination of pioneering scientific research and pre-clinical and clinical gene therapy product development expertise, along with advanced viral vector manufacturing experience,” said Serene Forte, Ph.D., MPH, senior vice president, head of genetic medicine at Relief Therapeutics. “It will be a privilege to work with Dr. Gao and benefit from his vast knowledge and advice in this space.”
In his advisory role, Dr. Gao will serve as an integral resource, providing scientific review and high-level technical and strategic guidance related to gene therapy targets, research and pre-clinical development and strategic research alliances as the Company works to expand its portfolio.
“The Relief Therapeutics team has built a strong foundation with their current portfolio and cost-effective capital approach to drug development,” said Dr. Gao. “I look forward to working with Dr. Forte and the highly capable leadership team to help build and proficiently execute the Relief Therapeutics genetic medicine program.”
Relief Therapeutics launched its genetic medicines initiative with the objective of developing life-altering, potentially curative therapies for patients suffering from devastating rare diseases that currently lack treatment options. The company is leveraging its strength and experience to identify monogenic disorders in therapeutic areas that align with its areas of focus, such as rare metabolic diseases. The SAB will support the Company’s genetic medicines initiative and additional appointments are forthcoming. To learn more about Relief Therapeutics’ approach to genetic medicine, please visit: https://www.relieftherapeutics.com/genetic-medicine.
“Dr. Gao’s extensive experience in the advancement of novel approaches to treat inherited rare diseases will be instrumental in helping us shape the direction of our genetic medicine portfolio,” said Jack Weinstein, chief executive officer at Relief Therapeutics. “We are honored to have Dr. Gao lead our new SAB and welcome him to Relief Therapeutic